
Themis Medicare Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 2- Themis Medicare expects a 35% CAGR growth over the next 2-3 years, driven primarily by hospital business expansion.
- Growth in hospital business is supported by building and adding specialized sales teams focused on hospitals.
- New product launches, including generics for emerging markets and new drug delivery systems, are planned but will take time due to regulatory approvals.
- The critical care portfolio is being developed steadily, with plans to introduce more teams and products over the next 3-4 years.
- Export markets remain a focus, targeting 40+ emerging markets with high-value generics.
- API business is expected to show improvement with a new manufacturing process.
- Domestic formulation business aims for first-launch opportunities with improved margins.
- Overall growth will leverage increased productivity without a significant rise in fixed sales force costs.
See what Themis Medicare management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company has taken on additional long-term borrowing (an increase of INR5 crore) in the form of a term loan from current bankers.
- This borrowing is meant to fund the ongoing capex plan, including facility upgrades in Haridwar, setting up R&D labs, and construction activities.
- There is no explicit mention of any planned new equity fundraising.
- The focus appears to be on organic growth supported by internal capex and operational improvements rather than fresh equity infusion.
- No specific details were shared about future debt or equity fundraising beyond the current term loan for capex.
See what Themis Medicare management said on order book — free account, 30 seconds.
Capex plans
Yes- FY23 capex totaled around INR 29 crores (net of depreciation), invested in:
- - Upgrading Haridwar facility (~INR 14.65 crores) for EU GMP compliance and additional injectable lines.
- - Enhancing Vapi factory capacity (~INR 11 crores).
- - Increasing R&D base in Hyderabad and setting up a new R&D lab in Baroda (~INR 1.17 crores).
- - Plant and machinery additions and building construction for refinement projects.
- Capex funded partly through increased long-term borrowing (~INR 5 crores term loan).
- Focus on strategic investments to support growth areas:
- - Injectable line upgrades and obtaining UDMP certification to open export opportunities.
- - Building critical care product portfolio aligned with hospital business focus.
- - Strengthening R&D with skilled manpower and infrastructure to drive future product development.
- Future investments expected to support expansion in hospital and API businesses, with a cautious approach to fixed costs.
Track Themis Medicare — get its next earnings analysis in your feed
How does Themis Medicare rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Themis Medicare rank in Pharmaceuticals & Biotechnology?
Compare Themis Medicare against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.